Galmed announces positive part 1 results from the am-001 study of aramchol meglumine, an enhanced formulation of the most clinically advanced scd1 inhibitor

– am-001 study represents a pivotal milestone in galmed's transition to aramchol meglumine, an improved formulation of its lead compound in advanced clinical development  – aramchol meglumine, a new chemical entity (nce) protected by patents until 2035, is being developed both as a standalone agent and in novel drug combinations for multiple indications influenced by fatty acid metabolism  – initial findings suggest that the new aramchol meglumine formulation offers higher bioavailability than aramchol free acid and that a once-daily, oral 200 mg dose is likely to be optimal for future trials, supporting improved patient compliance and potentially lowering manufacturing costs tel aviv, israel , april 10, 2025 /prnewswire/ -- galmed pharmaceuticals ltd. (nasdaq: glmd) ("galmed" or the "company"), a clinical-stage biopharmaceutical company focused on liver, cardiometabolic, and gastrointestinal oncology indications, today announced positive preliminary results from part 1 of the ph1 bioavailability am-001 study of aramchol meglumine.
GLMD Ratings Summary
GLMD Quant Ranking